An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent the longest reported remission to date in a patient treated with chimeric antigen receptor (CAR) T cell therapy. The findings, published in Nature Medicine, describe several long-term survivors in a follow-up from a phase 1 clinical trial
Analysis looked for—and did not find—examples where the process of generating CAR T cells caused malignancy Within a large group of more than 700 patients treated with CAR T cell therapy, researchers found no evidence that the therapy itself caused any type of secondary cancer in the modified T cells, according to new analysis reported
Novel research in cells and mice models has provided insight into the mechanisms that regulate trogocytosis, a process during which immune cells can exchange membrane-bound proteins. The study showed that chimeric antigen receptor cells (so-called CAR-T cells) could transfer tumour antigen-specific receptors to recipient T cells, and in doing so equipped the latter cells with tumour-targeting
Trial results supported recent FDA approval for patients with relapsed/refractory disease Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene autoleucel (obe-cel), experienced high response rates and most did not need a subsequent stem cell transplant (SCT), according to results from the
Study marks the first time these side effects were reported in children Researchers at Children’s Hospital of Philadelphia (CHOP) revealed for the first time that children, adolescents and young adults may experience very rare neurological issues of paraparesis and quadriparesis following chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy used to treat B-cell Acute
When the U.S. Food and Drug Administration (FDA) announced in November 2023 that it was investigating a link between receiving CAR T therapy and developing secondary cancers later on, it spurred uncertainty for patients and researchers alike. As many of the more than 30,000 patients who have received the life-saving treatment face new questions about
Scientists from UNIGE and HUG have developed CAR-T cells capable of targeting malignant gliomas while preserving healthy tissues. Glioblastoma is the most common and aggressive primary brain tumor—average survival after diagnosis is less than two years—and current treatments remain ineffective. In recent years, immunotherapies have been giving patients hope, albeit with relatively modest success. A
In an early Stanford Medicine study, CAR-T cell therapy helps some with intractable lymphoma, but those who relapse have few options. Modifying the therapy’s molecular target improved response. CAR-T cell therapy, which targets a specific protein on the surface of cancer cells, causes tumors to shrink or disappear in about half of patients with large
In April, the FDA warned of risk of secondary cancers in people receiving CAR-T cell therapy. A large Stanford Medicine study finds the risk is low and not related to the CAR-T cells. A large study by researchers at Stanford Medicine has found that the risk of secondary blood cancers after CAR-T cell therapy — a
Credit: Chinese Medical JournalDaishi Tian from Huazhong University of Science and Technology Autoimmune disease (AID) refers to the condition in which the immune system identifies the body’s own cells and tissues as foreign, resulting in systemic inflammation. The immune system’s self-attack via autoreactive B and T immune cells and autoantibodies—antibodies against body’s own proteins—may present
